Aclarubicin

Aclarubicin

SCHEMBL4532

CC[C@@]1(O)C[C@H](O[C@H]2C[C@H](N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)[C@H]1C(=O)OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 4/20 1.00
MMP2 P08253 3/20 1.00
HTR2B P41595 2/20 1.00
FNTA P49354 1/20 0.78
FNTB P49356 1/20 0.78
MEN1 O00255 12/20 0.77
KMT2A Q03164 12/20 0.77
RECQL P46063 8/20 0.77
MAPT P10636 7/20 0.77
SMN1; SMN2 Q16637 6/20 0.77
USP2 O75604 5/20 0.77
CYP3A4 P08684 5/20 0.77
TP53 P04637 3/20 0.77
HBB P68871 2/20 0.77
BLM P54132 10/20 0.67
THRB P10828 10/20 0.67
KDM4E B2RXH2 5/20 0.67
CASP1 P29466 2/20 0.67
HSD17B10 Q99714 2/20 0.67
BRCA1 P38398 5/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aclarubicin SCHEMBL2804048 1.00 PTGS1 (1.00) PTGS1MMP2HTR2BFNTAFNTB
Aclarubicin SCHEMBL29390785 1.00 PTGS1 (1.00) PTGS1MMP2HTR2BFNTAFNTB
Aclarubicin SCHEMBL31238004 1.00 PTGS1 (1.00) PTGS1MMP2HTR2BFNTAFNTB
Aclarubicin SCHEMBL1649619 1.00 PTGS1 (1.00) PTGS1MMP2HTR2BFNTAFNTB
Aclarubicin SCHEMBL10061856 1.00 PTGS1 (1.00) PTGS1MMP2HTR2BFNTAFNTB
Aclarubicin SCHEMBL10201119 1.00 PTGS1 (1.00) PTGS1MMP2HTR2BFNTAFNTB
Aclarubicin SCHEMBL10079204 1.00 PTGS1 (1.00) PTGS1MMP2HTR2BFNTAFNTB
Aclarubicin SCHEMBL17035568 1.00 PTGS1 (1.00) PTGS1MMP2HTR2BFNTAFNTB
Aclarubicin SCHEMBL6255351 1.00 PTGS1 (1.00) PTGS1MMP2HTR2BFNTAFNTB
Aclarubicin SCHEMBL31277372 1.00 PTGS1 (1.00) PTGS1MMP2HTR2BFNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 31830 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137671-A1 PDK4 as a Cell-Aging Intervention Target and Its Use in Chemotherapy and Anticancer SHANGHAI INST OF NUTRITION AND HEALTH CHINESE ACADEMY OF SCIENCES (CN) 2026-05-21 US claimed
US-20260137686-A1 SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF IMPACT THERAPEUTICS SHANGHAI INC (CN) 2026-05-21 US claimed
US-20260137794-A1 LIGAND-DRUG CONJUGATE AND USE THEREOF SYSTIMMUNE INC (US) 2026-05-21 US claimed
US-20260137685-A1 SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF IMPACT THERAPEUTICS SHANGHAI INC (CN) 2026-05-21 US claimed
WO-2026103267-A1 USE OF SESQUITERPENOIDS IN RELIEVING NAUSEA AND VOMITING 辽宁新中现代医药有限公司 2026-05-21 WO claimed
CN-122056884-A Methods of treating pancreatic cancer 坎莫森特里克斯公司 2026-05-19 CN claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
EP-4727589-A1 PROTAMINE-COATED NUCLEIC ACID/THERAPEUTIC AGENT COMPLEXES, AND USES THEREOF The Regents of the University of California (US) 2026-04-22 EP claimed
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2026-03-26 US claimed
US-12576077-B2 Composition for preventing, alleviating or treating cancer CKP THERAPEUTICS, INC. (US) 2026-03-17 US claimed
EP-0132105-A2 Oily composition of aclarubicin or hydrochloride thereof YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1985-01-23 EP claimed
EP-0050724-B1 PROCESS FOR ANTHRACYCLINE GLYCOSIDES F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1985-01-09 EP claimed
EP-0050725-B1 PROCESS FOR ACLACINOMYCINS AND MICROORGANISM USED THEREIN F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-07-04 EP claimed
EP-0110955-A1 BRAIN-SPECIFIC DRUG DELIVERY. UNIV FLORIDA (US) 1984-06-20 EP claimed
WO-1983003968-A1 BRAIN-SPECIFIC DRUG DELIVERY UNIVERSITY OF FLORIDA (US) 1983-11-24 WO claimed
US-4383037-A Process to produce anthracycline glycosides HOFFMANN-LA ROCHE INC. (US) 1983-05-10 US claimed
EP-0050724-A1 Process for anthracycline glycosides F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1982-05-05 EP claimed
US-4245045-A ENZYMATIC REDUCTION ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) 1981-01-13 US claimed
US-4219622-A ENZYMATIC REDUCTION OF CINERUBIN A OR ACLACINOMYCIN A; ANTITUMOR AGENTS ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) 1980-08-26 US claimed
US-4071411-A FERMENTATION OF STREPTOMYCES ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) 1978-01-31 US claimed